首页

Zhaoke's Innovative Presbyopia Drug, YUVEZZI™ Approved for Use at Boao Super Hospital in Hainan, China, as a Clinically Urgent Imported Drug

2026-07-07

191

Accelerating Global Layout | Zhaoke Ophthalmology Debuts at BIO 2026 and Signs Strategic MOU with Teuto of Brazil

2026-07-06

207

0.02% Strength of Atropine Sulfate Eye Drops Accepted for Regulatory Review in Australia

2026-06-15

592

Zhaoke Signs Partnership with PT. Erela for the Supply and Distribution of Zhaoke's CsA Ophthalmic Gel for Dry Eye Disease in Indonesia

2026-06-05

609

Zhaoke Ophthalmology Announces 2025 Annual Results

2026-03-25

8823

首页 1 2 3 4 5 尾页

Guangzhou Headquarters

Tel: 020-39062828

E-mail: info@zkoph.com

Add: No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangzhou

Hong Kong Headquarters

Tel: (852)23145100

E-mail: info@zkoph.com

Add: Unit 716, 7/F, Building 12W Phase 3, Hong Kong Science Park Shatin, Hong Kong

Wechat

Guangzhou Headquarters

Tel: 020-39062888

E-mail: info@zkoph.com

Add: No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangzhou

Hong Kong Headquarters

Tel: (852)23145100

E-mail: info@zkoph.com

Add: Unit 716, 7/F, Building 12W Phase 3, Hong Kong Science Park Shatin, Hong Kong

Wechat